Skip to main content Accessibility help
  • Print publication year: 2016
  • Online publication date: October 2016

Chapter 19 - Iatrogenic intracerebral hemorrhage due to oral anticoagulation therapy: risk factors and diagnosis

from Section VI - Iatrogenic hemorrhagic strokes: anticoagulation-related intracranial hemorrhage

Related content

Powered by UNSILO
1.Ogilvie, I M, Newton, N, Welner, S A, Cowell, W, Lip, G Y H. Underuse of oral anticoagulants in atrial fibrillation: A systematic review. Am J Med. 2010; 123:638–45.
2.Shroff, G R, Solid, C A, Herzog, C A. Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: A 15-year perspective (1992–2007). JAMA Intern Med. 2013; 173:159–60.
3.Connolly, S J, Ezekowitz, M D, Yusuf, S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–51.
4.Patel, M R, Mahaffey, K W, Garg, J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–91.
5.Granger, C B, Alexander, J H, McMurray, J J V, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365:981–92.
6.Connolly, S J, Eikelboom, J, Joyner, C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011; 364:806–17.
7.Giugliano, R P, Ruff, C T, Rost, N S, et al. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke. 2014; 45:2372–8.
8.Connolly, S J, Wallentin, L, Ezekowitz, M D, et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELY-ABLE) study. Circulation. 2013; 128:237–43.
9.Hart, R G, Diener, H C, Yang, S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: The RE-LY trial. Stroke. 2012; 43:1511–17.
10.Hankey, G J, Stevens, S R, Piccini, J P, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: The rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014; 45:1304–12.
11.Ruff, C T, Giugliano, R P, Braunwald, E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014; 383:955–62.
12.Gage, B F, Yan, Y, Milligan, P E, Waterman, A D, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006; 151:713–19.
13.Pisters, R, Lane, D A, Nieuwlaat, R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010; 138:1093–100.
14.Fang, M C, Go, A S, Chang, Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study. J Am Coll Cardiol. 2011; 58:395401.
15.Apostolakis, S, Lane, D A, Guo, Y, Buller, H, Lip, G Y. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: The AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol. 2012; 60:861–7.
16.Hart, R G, Boop, B S, Anderson, D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471–7.
17.Fang, M C, Go, A S, Chang, Y, Hylek, E M, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007; 120:700–5.
18.Steiner, T, Kaste, M, Forsting, M, et al. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Recommendations for the management of intracranial haemorrhage – part I: Spontaneous intracerebral haemorrhage. Cerebrovasc Dis. 2006; 22:294316.
19.Själander, A, Engström, G, Berntorp, E, Svensson, P. Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. J Intern Med. 2003; 254:434–8.
20.Go, A S, Hylek, E M, Phillips, K A, Chang, Y, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285:2370–5.
21.Franke, C L, de Jonge, J, van Swieten, J C, Op de Coul, A A, van Gijn, J. Intracerebral hematomas during anticoagulant treatment. Stroke. 1990; 21:726–30.
22.Flibotte, J J, Hagan, N, O’Donnell, J, Greenberg, S M, Rosand, J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004; 63:1059–64.
23.Sacco, S, Marini, C, Toni, D, Olivieri, L, Carolei, A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke. 2009; 40:394–9.
24.Horstmann, S, Rizos, T, Lauseker, M, et al. Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational study. J Neurol. 2013; 260:2046–51.
25.Lip, G Y, Andreotti, F, Fauchier, L, et al. Bleeding risk assessment and management in atrial fibrillation patients: A position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011; 13:723–46.
26.Petitti, D, Strom, B, Melmon, K. Duration of warfarin anticoagulation therapy and the probabilities or recurrent thromboembolism and hemorrhage. Am J Med. 1986; 81:255–9.
27.Fihn, S D, McDonnel, M, Martin, D, et al. Warfarin Optimized Outpatient Follow-up Study Group. Risk factors for complications of chronic anticoagulation: A multicenter study. Ann Intern Med. 1993; 118:511–20.
28.Palareti, G, Leali, N, Coccheri, S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996; 348:423–8.
29.Landefeld, C S, Goldman, L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989; 87:144–52.
30.Hart, R G, Tonarelli, S B, Pearce, L A. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke. 2005; 36:1588–93.
31.Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154:1449–57.
32.SPAF-Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke prevention in atrial fibrillation II study. Lancet. 1994; 343:687–91.
33.Olsson, S B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial. Lancet. 2003; 362:1691–8.
34.Albers, G W, Diener, H C, Frison, L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005; 293:690–8.
35.Di Marco, J P, Flaker, G, Waldo, A L, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2005; 149:650–6.
36.Landefeld, C S, Goldman, L. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989; 87:144–52.
37.van der Meer, F J, Rosendaal, F R, Vandenbroucke, J P, Briet, E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med. 1993; 153:1557–62.
38.Steffensen, F H, Kristensen, K, Ejlersen, E, Dahlerup, J F, Sorensen, H T. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med. 1997; 242:497503.
39.Beyth, R J, Quinn, L M, Landefeld, C S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998; 105:91–9.
40.Go, A S, Hylek, E M, Chang, Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: How well do randomized trials translate into clinical practice? JAMA. 2003; 290:2685–92.
41.Hylek, E M, Evans-Molina, C, Shea, C, Henault, L E, Regan, S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007; 115:2689–96.
42.Poli, D, Antonucci, E, Grifoni, E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009; 54:9991002.
43.Vandenbroucke, J P. Why do the results of randomised and observational studies differ? BMJ. 2011; 343:d7020.
44.Charidimou, A, Shakeshaft, C, Werring, D J. Cerebral microbleeds on magnetic resonance imaging and anticoagulant-associated intracerebral hemorrhage risk. Front Neurol. 2012; 19:133.
45.Larsen, T B, Rasmussen, L H, Skjøth, F, Due, K M, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: A prospective nationwide cohort study. J Am Coll Cardiol. 2013; 61:2264–73.
46.Southworth, M R, Reichman, M E, Unger, E F. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013; 368:1272–4.
47.Hankey, G J. Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: What have we learned? Curr Cardiol Rep. 2014; 16:480.
48.Wintzen, A R, De Jonge, H, Loeliger, E A, Botts, G T A M. The risk of intracerebral hemorrhage during oral anticoagulant treatment: A population study. Ann Neurol. 1984; 16:533–8.
49.Fisher, C M. Pathological observations in hypertensive cerebral hemorrhage. J Neuropathol Exp Neurol. 1971; 30:536–50.
50.Brouwers, H B, Goldstein, J N, Romero, J M, Rosand, J. Clinical applications of the computed tomography angiography spot sign in acute intracerebral hemorrhage: A review. Stroke. 2012; 43:3427–32.
51.Demchuk, A M, Dowlatshahi, D, Rodriguez-Luna, D, et al. PREDICT/Sunnybrook ICH CTA study group. Prediction of hematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): A prospective observational study. Lancet Neurol. 2012; 11:307–14.
52.Delgado Almandoz, J E, Yoo, A J, Stone, M J, et al. Systematic characterization of the computed tomography angiography spot sign in primary intracerebral hemorrhage identifies patients at highest risk for hematoma expansion: The spot sign score. Stroke. 2009; 40:29943000.
53.Brouwers, H B, Biffi, A, McNamara, K A, et al. Apolipoprotein E genotype is associated with CT angiography spot sign in lobar intracerebral hemorrhage. Stroke. 2012; 43:2120–5.
54.Brouwers, H B, Greenberg, S M. Hematoma expansion following acute intracerebral hemorrhage. Cerebrovasc Dis. 2013; 35:195201.
55.Greenberg, C H, Frosch, M P, Goldstein, J N, Rosand, J, Greenberg, S M. Modeling intracerebral hemorrhage growth and response to anticoagulation. PLoS One. 2012; 7:e48458.
56.Grysiewicz, R, Gorelick, P B. Incidence, mortality, and risk factors for oral anticoagulant-associated intracranial hemorrhage in patients with atrial fibrillation. J Stroke Cerebrovasc Dis. 2014; 23:2479–88.
57.Hylek, E M, Singer, D E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994; 120:897902.
58.Fang, M C, Chang, Y, Hylek, E M, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004; 16:745–52.
59.Stroke Prevention in Atrial Fibrillation (SPAF) II Study. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Lancet. 1994; 343:687–91.
60.Birman-Deych, E, Radford, M J, Nilasena, D S, Gage, B F. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006; 37:1070–4.
61.Shen, A Y, Yao, J F, Brar, S S, Jorgensen, M B, Chen, W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol. 2007; 50:309–15.
62.Hylek, E M, Go, A S, Chang, Y, Jensvold, N G, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349:1019–26.
63.Berwaerts, J, Webster, J. Analysis of risk factors involved in oral-anticoagulant-related intracranial haemorrhages. QJM. 2000; 93:513–21.
64.Fric-Shamji, E C, Shamji, M F, Cole, J, Benoit, B G. Modifiable risk factors for intracerebral hemorrhage: study of anticoagulated patients. Can Fam Physician. 2008; 54:1138–9.
65.The Stroke Prevention In Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol. 1997; 42:857–65.
66.Revesz, T, Holton, J L, Lashley, T, et al. Sporadic and familial cerebral amyloid angiopathies. Brain Pathol. 2002; 12:343–57.
67.Greenberg, S M, Rebeck, G W, Vonsattel, J P, Gomez-Isla, T, Hyman, B T. Apolipo-protein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol. 1995; 38:254–9.
68.Nicoll, J A, Burnett, C, Love, S, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol. 1997; 41:716–21.
69.Biffi, A, Sonni, A, Anderson, C D, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol. 2010; 68:934–43.
70.Rosand, J, Hylek, E M, O’Donnell, H C, Greenberg, S M. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study. Neurology. 2000; 55:947.
71.Melo, T P, Bogousslavsky, J, Regli, F, Janzer, R. Fatal hemorrhage during anticoagulation of cardioembolic infarction: Role of cerebral amyloid angiopathy. Eur Neurol. 1993: 33:912.
72.Flockhart, D A, O’Kane, D, Williams, M S, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008; 10:139–50.
73.Stehle, S, Kirchheiner, J, Lazar, A, Fuhr, U. Pharmacogenetics of oral anticoagulants: A basis for dose individualization. Clin Pharmacokinet. 2008; 47:565–94.
74.Higashi, M K, Veenstra, D L, Kondo, L M, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002; 287:1690–8.
75.Rybak, I, Ehle, M, Buckley, L, Fanikos, J. Efficacy and safety of novel anticoagulants compared with established agents. Ther Adv Hematol. 2011; 2:175–95.
76.Mega, J L, Walker, J R, Ruff, C T, et al. Genetics and the clinical response to warfarin and edoxaban: Findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015; 385:2280–7.
77.Shireman, T I, Howard, P A, Kresowik, T F, Ellerbeck, E F. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004; 35:2362–7.
78.Gouw, A A, Seewann, A, Van Der Flier, W M, et al. Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatr. 2010; 82:126–35.
79.Schmidt, R, Grazer, A, Enzinger, C, et al. MRI-detected white matter lesions: Do they really matter? J Neural Transm. 2011; 118:673–81.
80.Gorter, J W. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999; 53:1319–27.
81.Smith, E E, Rosand, J, Knudsen, K A, Hylek, E M, Greenberg, S M. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology. 2002; 59:193–7.
82.Greenberg, S M, Vernooij, M W, Cordonnier, C, et al. Cerebral microbleeds: A guide to detection and interpretation. Lancet Neurol. 2009; 8:165–74.
83.Lee, S H, Ryu, W S, Roh, J K. Cerebral microbleeds are a risk factor for warfarin-related intracerebral hemorrhage. Neurology. 2009; 72:171–6.
84.Ueno, H, Naka, H, Ohshita, T, et al. Association between cerebral microbleeds on T2*-weighted MR images and recurrent hemorrhagic stroke in patients treated with warfarin following ischemic stroke. Am J Neuroradiol. 2008; 29:1483–6.
85.Lovelock, C E, Cordonnier, C, Naka, H, et al. Edinburgh Stroke Study Group. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: a systematic review of published and unpublished studies. Stroke. 2010; 41:1222–8.
86.Charidimou, A, Peeters, A P, Jäger, R, et al. Cortical superficial siderosis and intracerebral hemorrhage risk in cerebral amyloid angiopathy. Neurology. 2013; 81:1666–73.
87.Kidwell, C S, Chalela, J A, Saver, J L, et al. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA. 2004; 292:1823–30.
88.Greenberg, S M, Eng, J A, Ning, M, Smith, E E, Rosand, J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke. 2004; 35:1415–20.
89.Cucchiara, B, Messe, S, Sansing, L, Kasner, S, Lyden, P; CHANT Investigators. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008; 39:2993–6.
90.Flaherty, M L, Tao, H, Haverbusch, M, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008; 71:1084–9.
91.Sheth, K N, Cushing, T A, Wendell, L, et al. Comparison of hematoma shape and volume estimates in warfarin versus non-warfarin-related intracerebral hemorrhage. Neurocrit Care. 2010; 12:30–4.
92.Levine, J M, Snider, R, Finkelstein, D, et al. Early edema in warfarin-related intracerebral hemorrhage. Neurocrit Care. 2007; 7:5863.
93.Biffi, A, Battey, T W, Ayres, A M, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology. 2011; 15:1840–6.
94.Kase, C S, Robinson, R K, Stein, R W, et al. Anticoagulant-related intracerebral hemorrhage. Neurology. 1985; 35:943–8.
95.Toyoda, K, Okada, Y, Ibayashi, S, et al. Antithrombotic therapy and predilection for cerebellar hemorrhage. Cerebrovasc Dis. 2007; 23:109.
96.Brott, T, Broderick, J, Kothari, R, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke. 1997; 28:15.
97.Balami, J S, Buchan, A M. Complications of intracerebral haemorrhage. Lancet Neurol. 2012; 11:101–18.
98.Veltkamp, R, Rizos, T, Horstmann, S. Intracerebral bleeding in patients on antithrombotic agents. Semin Thromb Hemost. 2013; 39:963–71.
99.Sjöblom, L, Hårdemark, H G, Lindgren, A, et al. Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: A Swedish multicenter study. Stroke. 2001; 32:2567–74.
100.Rosand, J, Eckman, M H, Knudsen, K A, Singer, D E, Greenberg, S M. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004; 164:880–4.
101.Zubkov, A Y, Mandrekar, J N, Claassen, D O, et al. Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol. 2008; 65:1320–5.